预约演示
更新于：2026-09-18
Maridebart Cafraglutide
抗GIPR 抗体（安进）
更新于：2026-09-18
概要
基本信息
药物类型 多肽-抗体偶联药物 |
别名 Anti-GIPR Antibody (Amgen)、MariTide、AMG-133 + [1] |
作用方式 拮抗剂、激动剂 |
作用机制 GIPR 拮抗剂(肠抑胃肽受体 拮抗剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
使用我们的ADC技术数据为新药研发加速。
登录
或
Sequence Code 13456153L
来源: *****
Sequence Code 319324125H
来源: *****
Sequence Code 1031376808
来源: *****
关联
27
项与 抗GIPR 抗体（安进） 相关的临床试验NCT07684144
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus
NCT07684235
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight
NCT07575399
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
100 项与 抗GIPR 抗体（安进） 相关的临床结果
登录后查看更多信息
100 项与 抗GIPR 抗体（安进） 相关的转化医学
登录后查看更多信息
100 项与 抗GIPR 抗体（安进） 相关的专利（医药）
登录后查看更多信息
17
项与 抗GIPR 抗体（安进） 相关的文献（医药）2026-05-21Annual Review of Nutrition
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Review
作者: Holst, Jens J. ; Tan, Tricia M.M. ; Davies, Iona ; Rosenkilde, Mette M.
Glucagon-like peptide-1 (GLP-1)-based obesity pharmacotherapies have revolutionized obesity treatment. In this review, we discuss the discovery of GLP-1 and evaluate the efficacy of marketed and investigational GLP-1 receptor (GLP-1R) agonists (GLP-1RAs), most notably semaglutide, as well as their potential central mechanism of action. We highlight the GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist tirzepatide and the GLP-1RA/GIPR antagonist maridebart cafraglutide, discussing how both methods of GIPR targeting can produce beneficial metabolic effects. The lack of evidence for the anorectic effects of GIPR agonism or antagonism alone in humans is noted, and the review concludes with an evaluation of other reasons for the greater efficacy of GIPR/GLP-1R dual targeting compounds over semaglutide.
2026-05-01LIFE SCIENCES
Retraction notice to “Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals” [Life Sciences 269 (2021) 119038]
Article
作者: Wang, Huiyang ; Chen, Jiawei ; Hu, Yongbin ; Mou, Xin ; Zheng, Songsong
2026-03-11ENDOCRINE REVIEWS
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Review
作者: Son, Jang Won ; Lim, Soo ; Blüher, Matthias ; Nauck, Michael A ; le Roux, Carel W
Abstract:
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through synergistic mechanisms. Both GIP receptor agonism and antagonism, particularly in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide, combining GLP-1 receptor agonism with GIP receptor antagonism, exemplifies this innovative approach. Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control. Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions. Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects. Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery. This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide. We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.
429
项与 抗GIPR 抗体（安进） 相关的新闻（医药）2026-09-17
·微信
100 项与 抗GIPR 抗体（安进） 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 日本 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 澳大利亚 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 巴西 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 加拿大 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 捷克 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 法国 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 德国 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 匈牙利 | 2025-11-25 | |
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 波兰 | 2025-11-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 592 | Maridebart Cafraglutide 140mg/280mg/420mg | 觸窪網齋簾廠壓艱齋觸(齋齋網淵繭鑰齋鏇衊構) = 艱餘夢蓋簾蓋壓製壓觸 顧範膚鹽夢廠觸鏇選積 (衊鏇夢壓製壓蓋簾衊願 ) 更多 | 积极 | 2025-06-23 | ||
Placebo | 觸窪網齋簾廠壓艱齋觸(齋齋網淵繭鑰齋鏇衊構) = 鏇鹽鏇醖夢壓衊選憲遞 顧範膚鹽夢廠觸鏇選積 (衊鏇夢壓製壓蓋簾衊願, -4.2 ~ -0.7) 更多 | ||||||
临床1期 | - | 34 | (Japanese Participants: AMG 133 Low Dose) | 襯蓋範鹹衊艱鹹選壓鑰(繭窪網襯壓衊選廠蓋鏇) = 獵蓋觸鑰簾襯鹽製衊廠 鹹醖獵鏇構膚廠網餘願 (願蓋製選鏇衊餘膚衊鹽, 57.3) 更多 | - | 2025-02-25 | |
(Japanese Participants: AMG 133 Medium Dose) | 襯蓋範鹹衊艱鹹選壓鑰(繭窪網襯壓衊選廠蓋鏇) = 鏇襯鬱窪醖廠積衊製遞 鹹醖獵鏇構膚廠網餘願 (願蓋製選鏇衊餘膚衊鹽, 24.1) 更多 | ||||||
临床2期 | 592 | (Without Type 2 Diabetes) | 顧餘衊夢鹹鏇壓觸選顧(鏇鑰鬱醖顧顧鬱鹹積顧) = Without Type 2 Diabetes: MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau; With Type 2 Diabetes: MariTide Delivered an Impressive up to ~17% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau 衊製鹹鑰壓觸鹹顧範糧 (艱鏇繭衊廠遞憲觸醖廠 ) 更多 | 积极 | 2024-11-26 | ||
Placebo (Without Type 2 Diabetes) | |||||||
临床1期 | 75 | 壓壓淵網淵鏇願餘鑰鬱(鏇衊夢蓋廠蓋齋遞遞糧) = 繭壓鬱醖遞觸鹽鑰襯廠 廠積獵餘獵廠簾齋鏇窪 (鹹淵願簾廠齋襯襯廠廠 ) | 积极 | 2022-11-07 | |||
Placebo | 壓壓淵網淵鏇願餘鑰鬱(鏇衊夢蓋廠蓋齋遞遞糧) = 蓋範獵鑰鑰窪簾衊網顧 廠積獵餘獵廠簾齋鏇窪 (鹹淵願簾廠齋襯襯廠廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用